• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

扩张型心肌病的长期β受体阻滞剂治疗。短期和长期美托洛尔治疗后停药及重新给药的效果。

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

作者信息

Waagstein F, Caidahl K, Wallentin I, Bergh C H, Hjalmarson A

机构信息

Department of Medicine I, University of Gothenburg, Sweden.

出版信息

Circulation. 1989 Sep;80(3):551-63. doi: 10.1161/01.cir.80.3.551.

DOI:10.1161/01.cir.80.3.551
PMID:2548768
Abstract

To evaluate the short- and long-term effects of beta-adrenergic blockade (metoprolol) as well as the reaction to withdrawal and readministration of metoprolol in severe heart failure, 33 patients (25 men and eight women; mean age, 47.6 +/- 14.0 years) with dilated cardiomyopathy were studied by right and left heart catheterization, right ventricular biopsy, two-dimensional and Doppler echocardiography, and external pulse recordings. Twenty-six of 33 patients survived more than 6 months, and 24 of the 26 patients improved their functional class (from mean 3.3 to 1.8, p less than 0.0001). These 24 patients were subjected to withdrawal of metoprolol until the number of symptoms increased and deterioration occurred as observed noninvasively (group 1, n = 16), whereas the eight patients did not deteriorate during a 12-month period (group 2). During long-term treatment with metoprolol, there was an increase in ejection fraction from 0.24 to 0.42 (p less than 0.0001), whereas there was a decrease in the left ventricular (LV) end-diastolic dimension (from 7.3 to 6.4 cm, p less than 0.0001), in the grade of mitral regurgitation (from 1.7 to 0.4, p less than 0.0001), and in the grade of tricuspid regurgitation (from 0.6 to 0.05, p less than 0.007). There was a decrease in pulmonary wedge pressure (from 23.8 to 10.7 mm Hg, p less than 0.0001), LV end-diastolic pressure (from 24.1 to 13.4 mm Hg, p less than 0.002), and systolic vascular resistance (from 1,782 to 1,499 dynes/sec/cm, p less than 0.04). There was an increase in systolic blood pressure (from 116 to 132 mm Hg, p less than 0.003), cardiac index (from 2.17 to 2.58 l/min/m2, p less than 0.005), and LV stroke work index (from 31 to 65 g.m/m2, p less than 0.0001). During withdrawal of metoprolol, the heart rate and left atrial dimension increased (p less than 0.0001), whereas ejection fraction decreased (p less than 0.0001). The 12 (of 16) patients in group 1 who survived the withdrawal period had metoprolol readministered, and subsequently, ejection fraction increased (from 0.23 to 0.33, p less than 0.002). Patients had a low number of ventricular beta-adrenergic receptors compared with healthy control subjects (30.3 +/- 2.9 vs. 97.4 +/- 8.7 fmol/mg protein, p less than 0.001), but long-term treatment with metoprolol caused a moderate up-regulation (from 30.3 +/- 2.9 to 49.0 +/- 7.1 fmol/mg protein, p less than 0.05), which may facilitate a more normal response to sympathetic stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

为评估β-肾上腺素能阻滞剂(美托洛尔)的短期和长期疗效,以及重度心力衰竭患者停用和重新服用美托洛尔后的反应,我们通过右心和左心导管检查、右心室活检、二维及多普勒超声心动图以及外部脉搏记录,对33例扩张型心肌病患者(25例男性和8例女性;平均年龄47.6±14.0岁)进行了研究。33例患者中有26例存活超过6个月,这26例患者中有24例心功能分级得到改善(从平均3.3级改善至1.8级,p<0.0001)。这24例患者被停用美托洛尔,直至出现症状数量增加及非侵入性观察到的病情恶化(第1组,n = 16),而另外8例患者在12个月期间病情未恶化(第2组)。在美托洛尔长期治疗期间,射血分数从0.24增加至0.42(p<0.0001),而左心室舒张末期内径减小(从7.3 cm减小至6.4 cm,p<0.0001),二尖瓣反流程度降低(从1.7降至0.4,p<0.0001),三尖瓣反流程度降低(从0.6降至0.05,p<0.007)。肺楔压降低(从23.8 mmHg降至10.7 mmHg,p<0.0001),左心室舒张末期压力降低(从24.1 mmHg降至13.4 mmHg,p<0.002),收缩期血管阻力降低(从1782达因/秒/厘米降至1499达因/秒/厘米,p<0.04)。收缩压升高(从116 mmHg升至132 mmHg,p<0.003),心脏指数升高(从2.17升/分钟/平方米升至2.58升/分钟/平方米,p<0.005),左心室每搏功指数升高(从31克·米/平方米升至65克·米/平方米,p<0.0001)。在停用美托洛尔期间,心率和左心房内径增加(p<0.0001),而射血分数降低(p<0.0001)。第1组中16例存活过撤药期的患者重新服用美托洛尔,随后射血分数升高(从0.23升至0.33,p<0.002)。与健康对照受试者相比,患者的心室β-肾上腺素能受体数量较少(30.3±2.9对97.4±8.7飞摩尔/毫克蛋白,p<0.001),但美托洛尔长期治疗导致中度上调(从30.3±2.9升至49.0±7.1飞摩尔/毫克蛋白,p<0.05),这可能有助于对交感神经刺激产生更正常的反应。(摘要截断于400字)

相似文献

1
Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.扩张型心肌病的长期β受体阻滞剂治疗。短期和长期美托洛尔治疗后停药及重新给药的效果。
Circulation. 1989 Sep;80(3):551-63. doi: 10.1161/01.cir.80.3.551.
2
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy.美托洛尔长期治疗充血性心力衰竭后运动射血分数增加及心脏重构逆转:一项针对缺血性或特发性扩张型心肌病所致轻至中度心力衰竭的随机、分层、双盲、安慰剂对照试验。
Eur J Heart Fail. 2003 Oct;5(5):679-91. doi: 10.1016/s1388-9842(03)00105-3.
3
Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? The Heart Muscle Disease Study Group.美托洛尔治疗扩张型心肌病:能否识别出预测改善情况的因素?心肌疾病研究组
J Card Fail. 1996 Jun;2(2):87-102. doi: 10.1016/s1071-9164(96)80027-3.
4
Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.在扩张型心肌病所致心力衰竭患者长期美托洛尔治疗期间,β受体密度增加,对儿茶酚胺刺激的血流动力学反应改善。
Circulation. 1989 Mar;79(3):483-90. doi: 10.1161/01.cir.79.3.483.
5
Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.美托洛尔口服β受体阻滞剂治疗慢性重度扩张型心肌病
J Am Coll Cardiol. 1984 Jan;3(1):203-9. doi: 10.1016/s0735-1097(84)80449-0.
6
Reductions in muscle sympathetic nerve activity after long-term metoprolol for dilated cardiomyopathy: preliminary observations.长期使用美托洛尔治疗扩张型心肌病后肌肉交感神经活动的降低:初步观察
Br Heart J. 1995 Oct;74(4):431-6. doi: 10.1136/hrt.74.4.431.
7
Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction.长期肾上腺素能β受体阻滞剂对急性心肌梗死患者左心室舒张期充盈的影响。
Am Heart J. 1999 Oct;138(4 Pt 1):710-20. doi: 10.1016/s0002-8703(99)70187-0.
8
Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.β-肾上腺素能阻滞剂治疗的充血性心力衰竭患者左心室功能、质量和几何形状改善的时间进程。
J Am Coll Cardiol. 1995 Apr;25(5):1154-61. doi: 10.1016/0735-1097(94)00543-y.
9
Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy.普萘洛尔对扩张型心肌病早期耐受性及长期影响的血流动力学预测因素
J Card Fail. 1996 Dec;2(4):273-7. doi: 10.1016/s1071-9164(96)80013-3.
10
The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol.急性血流动力学肾上腺素能β受体阻滞剂与心力衰竭患者长期效应之间的联系。一项关于静脉注射美托洛尔后舒张功能、心率和心肌代谢的研究。
Eur Heart J. 1993 Oct;14(10):1375-85. doi: 10.1093/eurheartj/14.10.1375.

引用本文的文献

1
Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors.弥合人诱导多能干细胞衍生心肌细胞(hiPSC-CMs)心脏毒性评估与临床左心室射血分数(LVEF)下降风险之间的差距:21种酪氨酸激酶抑制剂的案例研究
Pharmaceuticals (Basel). 2025 Mar 23;18(4):450. doi: 10.3390/ph18040450.
2
Prognostic Implications of Guideline-Directed Medical Therapy for Heart Failure in Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis.功能性二尖瓣反流患者心力衰竭的指南指导药物治疗的预后意义:一项系统评价和荟萃分析
Diagnostics (Basel). 2025 Mar 1;15(5):598. doi: 10.3390/diagnostics15050598.
3
Medical Management and Device-Based Therapies in Chronic Heart Failure.
慢性心力衰竭的药物治疗与基于器械的疗法
J Soc Cardiovasc Angiogr Interv. 2023 Dec 4;2(6Part B):101206. doi: 10.1016/j.jscai.2023.101206. eCollection 2023 Nov-Dec.
4
Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy.射血分数改善的心力衰竭:患病率、预测因素及指南指导的药物治疗
Cureus. 2024 Jun 6;16(6):e61790. doi: 10.7759/cureus.61790. eCollection 2024 Jun.
5
Modulation of cAMP/cGMP signaling as prevention of congenital heart defects in Pde2A deficient embryos: a matter of oxidative stress.环磷酸腺苷/环鸟苷酸信号转导调控在 PDE2A 缺陷胚胎先天性心脏缺陷预防中的作用:氧化应激的影响。
Cell Death Dis. 2024 Feb 23;15(2):169. doi: 10.1038/s41419-024-06549-1.
6
Your Heart Function Has Normalized-What Next After TRED-HF?您的心脏功能已恢复正常——经导管修复射血分数降低的心力衰竭(TRED-HF)后接下来该怎么做?
Curr Heart Fail Rep. 2023 Dec;20(6):542-554. doi: 10.1007/s11897-023-00636-8. Epub 2023 Nov 24.
7
Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology.心力衰竭中的交感-肾上腺素能机制:病理生理学新见解
Med Rev (2021). 2021 Oct 21;1(1):47-77. doi: 10.1515/mr-2021-0007. eCollection 2021 Oct.
8
Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.基于心力衰竭短期治疗反应的血管紧张素受体-脑啡肽酶抑制剂的长期影响。
ESC Heart Fail. 2023 Dec;10(6):3430-3437. doi: 10.1002/ehf2.14505. Epub 2023 Sep 13.
9
Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction.急性心肌梗死后射血分数恢复的心力衰竭患者停用肾素-血管紧张素-醛固酮系统抑制剂的预后。
Sci Rep. 2023 Mar 2;13(1):3539. doi: 10.1038/s41598-023-30700-1.
10
Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction.射血分数改善的心力衰竭患者停用螺内酯的理论依据与研究设计
Int J Heart Fail. 2021 Jan 14;3(1):51-58. doi: 10.36628/ijhf.2020.0044. eCollection 2021 Jan.